Daewoong Pharmaceutical expands AI into drug formulation design with $4M project

by@CogAbility

Summary

Daewoong Pharmaceutical has launched a $4 million project, funded by the South Korean government, to expand the use of artificial intelligence (AI) in drug formulation design. Selected as the lead institution for the Ministry of Trade, Industry and Energy's initiative, Daewoong aims to develop an AI-based optimal design platform for modified-release and combination formulations, collaborating with universities and AI firms. This project, set to run until December 2029, intends to shift pharmaceutical formulation from traditional, experience-based methods to a data-driven approach, leveraging AI to recommend suitable formulations based on desired drug characteristics. As the pharmaceutical industry increasingly integrates AI beyond drug discovery, this project reflects broader governmental support for AI applications in manufacturing processes, with hopes of commercializing the technology through a subscription platform for external pharmaceutical firms.

Tokens

$KRW

Analysis

AIJPharm: AIJPharm is a South Korean company specializing in artificial intelligence applications for pharmaceutical technology. It joins the government-funded consortium to integrate explainable machine learning and Design of Experiments methods into formulation design. Park Sung-soo: Park Sung-soo is the CEO of Daewoong Pharmaceutical. He has highlighted the importance of formulation research in determining drug performance and patient convenience, emphasizing the project's goal of combining accumulated data with AI for improved research speed and precision. Kookmin University: Kookmin University is a South Korean research university participating in collaborative projects in technology and health sciences. It is part of the research consortium developing the AI-based formulation design platform alongside Daewoong Pharmaceutical and other partners. Chung-Ang University: Chung-Ang University is a South Korean research university with expertise in pharmaceutical and engineering fields. It contributes to the consortium's work on AI-driven drug formulation optimization and biorelevant testing systems. Daewoong Pharmaceutical: Daewoong Pharmaceutical is a South Korean pharmaceutical company focused on drug development and manufacturing. It is leading a national research project to build an AI platform for optimizing modified-release and combination drug formulations by working backward from target pharmacokinetic profiles. The company will handle GMP pilot production and explore commercializing the technology as a web-based subscription platform. AI in Formulation: Pharmaceutical companies are extending artificial intelligence applications from drug discovery into formulation design to reduce reliance on trial-and-error experimentation. Government Support: South Korea's Ministry of Trade, Industry and Energy is backing national projects that integrate AI with pharmaceutical manufacturing processes. Platform Commercialization: Research efforts in AI-driven formulation are moving toward subscription-based platforms intended for broader use by external pharmaceutical and biotechnology organizations.

Categories

machine_learningtechaiai_agentspolitics
View Original Tweet